Sudeep Pharma IPO...
19 Nov, 2025
Aptus Pharma IPO
Aptus Pharma Ltd is launching its SME IPO from September 23 to 25, 2025, with shares priced between ₹65 and ₹70 each. The Aptus Pharma IPO size is ₹13.02 crore through a fresh issue of approximately 18,60,000 shares. The minimum lot size is 2,000 shares, requiring an investment of about ₹1.3 lakh. The IPO will list on BSE SME, with allotment scheduled for September 26, 2025, refunds starting September 29, and listing expected on September 30, 2025.
Company Background
Aptus Pharma, established in 2010 and headquartered in Gujarat, markets a wide range of pharmaceutical products across multiple therapeutic areas. The company does not own manufacturing units but works with contract manufacturers to supply formulations in several categories, like anti-infectives, gastrointestinal, anti-allergic, nutritional supplements, and more. It serves diverse healthcare professionals, including general practitioners and specialists.
Operations And Product Range
Facility And Production
Aptus Pharma operates on a contract manufacturing model, sourcing products from seven reputed manufacturers. The company focuses on marketing, sales, and distribution while ensuring quality through strict vendor selection and control processes. Its supply chain is supported by strong distributor and stockist networks.
Brands And Market Presence
The Aptus Pharma IPO company’s brands are widely recognised in the healthcare segment due to their presence across multiple therapy areas. Its products reach customers mainly through pharma distributors and retailers across India, supported by a robust sales and marketing infrastructure, which includes a dedicated field force catering to healthcare professionals.
Revenue Channels
- • Marketing and sales of pharmaceutical formulations across diverse therapy categories.
- • Contract manufacturing partnerships with seven manufacturing units.
- • Distribution through a network of stockists and wholesalers across India.
- • Sales to hospitals, clinics, and pharmacies catering to various medical specialists.
Management And Shareholding
Promoters And Shareholding
The promoters of Aptus Pharma IPO hold significant stakes and are actively involved in the company’s strategic and operational decisions. The promoter group includes experienced professionals from the pharmaceutical domain who guide the company’s growth and compliance frameworks. The IPO will dilute the promoter’s stake, broadening the company’s equity base while ensuring promoter control remains.
Board Members
The board of directors comprises the promoter directors along with independent professionals who oversee audit, governance, risk management, and compliance matters. This mix ensures transparency, accountability, and strategic guidance necessary for a growing pharmaceutical marketer preparing for expanded visibility in public markets.
WHAT IS GMP?
GMP (Grey Market Premium) is the difference between the IPO price and the grey market price. It is the premium amount paid for the traded IPO shares. It plays an important role in IPOs as it reflects how the IPO would react on the listing day.
A grey market is a place where shares/stocks are traded before being listed officially on the stock exchange.
Aptus Pharma IPO
| GMP Date | IPO Price | GMP | Last Updated |
|---|---|---|---|
| - | - | - | - |
**The GMP prices displayed here are solely for informational purposes related to the grey market news. India IPO does not engage in or facilitate grey market trading, nor are these rates (sub2) indicative of any trading activity. We also do not recommend or endorse participation in the grey market.**
Aptus Pharma IPO Details
| Detail | Description |
|---|---|
| IPO Date | September 23, 2025 to September 25, 2025 |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Issue Price Band | ₹65 to ₹70 per share |
| Lot Size | 2,000 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 18,60,000 shares (aggregating up to ₹13.02 Cr) |
| Reserved for Market Maker | 94,000 shares (aggregating up to ₹0.6580 Cr) Market-Hub Stock Broking Pvt.Ltd. |
| Net Offered to Public | 17,66,000 shares (aggregating up to ₹12.36 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 50,00,000 shares |
| Share Holding Post Issue | 68,60,000 shares |
Aptus Pharma IPO Timeline
| Detail | Description |
|---|---|
| IPO Open Date | Tue, Sep 23, 2025 |
| IPO Close Date | Thu, Sep 25, 2025 |
| Tentative Allotment | Fri, Sep 26, 2025 |
| Initiation of Refunds | Mon, Sep 29, 2025 |
| Credit of Shares to Demat | Mon, Sep 29, 2025 |
| Tentative Listing Date | Tue, Sep 30, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Thu, Sep 25, 2025 |
Aptus Pharma IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 4,000 | ₹2,80,000 |
| Individual investors (Retail) (Max) | 2 | 4,000 | ₹2,80,000 |
| S-HNI (Min) | 3 | 6,000 | ₹4,20,000 |
| S-HNI (Max) | 7 | 14,000 | ₹9,80,000 |
| B-HNI (Min) | 8 | 16,000 | ₹11,20,000 |
Aptus Pharma IPO Promoter Holding
| Share Holding Pre Issue | Share Holding Post Issue |
|---|---|
| Promoter Holding Pre Issue | 100% |
| Promoter Holding Post Issue | 72.89% |
Competitive Strength:
- • Raise working capital to support increased inventory and distribution reach.
- • Strengthen marketing and sales efforts to expand market share in therapeutic segments.
- • Enhance corporate infrastructure, governance, and systems for compliance
- • General corporate purposes to support operational and strategic growth.
Aptus Pharma IPO Financial Information
| Period Ended | Assets | Revenue | Profit After Tax | Net Worth | Total Borrowing | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar 2025 | 21.92 | 24.64 | 3.1 | 6.97 | 10.36 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2024 | 10 | 18 | 1 | 2 | 5 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2023 | 6.22 | 13.90 | 0.19 | 0.97 | 2.21 | |||||||||||||||||||||||||||||||||||
| Amount in ₹ Crore | ||||||||||||||||||||||||||||||||||||||||
Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 44.50% |
| ROCE | 45.66% |
| Debt/Equity | 1.49 |
| RoNW | 44.50% |
| EBITDA Margin | 19.31% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 6.2 | 5 |
| P/E (x) | 11.29 | 15 |
IPO Objectives
- • Raise working capital to support increased inventory and distribution reach.
- • Strengthen marketing and sales efforts to expand market share in therapeutic segments.
- • Enhance corporate infrastructure, governance, and systems for compliance.
- • General corporate purposes to support operational and strategic growth.
Conclusion
Aptus Pharma IPO offers investors an opportunity to invest in a fast-growing pharmaceutical marketing company with a diversified product range and established B2B relationships. The company’s asset-light business model and strong financial performance underscore its potential for scale. The IPO proceeds will help accelerate growth, enhance market presence, and improve operational efficiencies.
RHP:
DRHP:
Read more :
Frequently asked Questions (FAQs )
-
What are the Aptus Pharma IPO dates and price band?
The IPO opens on September 23, 2025 and closes on September 25. The price band is ₹65 to ₹70 per share with a face value of ₹10.
-
How much is the issue size and minimum investment?
The issue size is ₹13.02 crore, with a minimum lot size of 2,000 shares, translating to about ₹1.3 lakh minimum investment.
-
What is the business model of Aptus Pharma IPO?
Aptus Pharma operates as a pharmaceutical marketer and distributor using a contract manufacturing model to offer various formulations across therapeutic categories without owning production facilities.
-
Who are the promoters of Aptus Pharma IPO?
The promoters are experienced pharmaceutical professionals who actively manage operations and strategic growth.
-
Where does the company sell its products?
The company serves hospitals, clinics, retailers, and pharmacies across India through a widespread distributor network.
-
How will the Aptus Pharma IPO funds be used?
The funds will be used for working capital to increase inventory and distribution, marketing expansion, corporate strengthening, and general business growth.
.jpg)
